Approach document for dyslipidemia. Spanish Society of Atherosclerosis (part II)

[1]  V. Kamanna,et al.  Mechanism of action of niacin. , 2008, The American journal of cardiology.

[2]  A. Goldberg,et al.  Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. , 2009, Endocrinology and metabolism clinics of North America.

[3]  E. Schiffrin,et al.  Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. , 2009, The American journal of medicine.

[4]  J. Mckenney,et al.  Safety considerations with gastrointestinally active lipid-lowering drugs. , 2007, The American journal of cardiology.

[5]  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001 .

[6]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[7]  A. Troendle,et al.  Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). , 2003, The American journal of cardiology.

[8]  J. Tomassini,et al.  Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. , 2008, Journal of the American College of Cardiology.

[9]  J. Tomassini,et al.  Ezetimibe : cholesterol lowering & beyond , 2007 .

[10]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[11]  E. Stein.  Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor , 2001 .

[12]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[13]  R. Califf,et al.  Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. , 2008, American heart journal.

[14]  G. Assmann.  Dyslipidaemia and global cardiovascular risk: clinical issues , 2006 .

[15]  Sandra J Lewis,et al.  Prevention and treatment of atherosclerosis: a practitioner's guide for 2008. , 2009, The American journal of medicine.

[16]  S. Grundy,et al.  Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus , 2006, Diabetes Care.

[17]  G. Watts,et al.  Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) , 1992, The Lancet.

[18]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[19]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[20]  J. Basile,et al.  Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study. , 2009, Journal of clinical lipidology.

[21]  M. Chapman.  Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. , 2003, Atherosclerosis.

[22]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[23]  A. Gotto,et al.  Update on Statins: 2003 , 2004, Circulation.

[24]  J. Fildes,et al.  Pleiotropic Effects and Cholesterol-Lowering Therapy , 2008, Cardiology.

[25]  Diabetes Atherosclerosis Intervention Study Investigators.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.

[26]  C. Furberg,et al.  Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). , 2005, The American journal of cardiology.

[27]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[28]  L. Iughetti,et al.  Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: A review , 2007, Journal of endocrinological investigation.

[29]  P. Mitchell,et al.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.

[30]  S. Kashiwagi,et al.  Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). , 2002, Journal of the American College of Cardiology.

[31]  A. Corsini,et al.  Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[32]  A. Zwinderman,et al.  Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.

[33]  C. Ballantyne,et al.  Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. , 2009, The American journal of cardiology.

[34]  B. Staels.  A Review of Bile Acid Sequestrants: Potential Mechanism(s) for Glucose-Lowering Effects in Type 2 Diabetes Mellitus , 2009, Postgraduate medicine.

[35]  Meehyung Cho,et al.  Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. , 2002, The American journal of cardiology.

[36]  W. Mack,et al.  Beneficial Effects of Colestipol‐Niacin Therapy on the Common Carotid Artery. Two‐ and Four‐Year Reduction of Intima‐Media Thickness Measured by Ultrasound , 1993, Circulation.

[37]  Jeannie K. Lee,et al.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.

[38]  J. Mckenney.  Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction. , 2002, The American journal of cardiology.

[39]  M. Castro Cabezas,et al.  Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins. , 2006, Journal of the American Dietetic Association.

[40]  Michael Miller,et al.  Extended-release niacin or ezetimibe and carotid intima-media thickness. , 2009, The New England journal of medicine.

[41]  C. Ballantyne,et al.  Combination therapy for combined dyslipidemia. , 2002, The American journal of cardiology.

[42]  Curt D. Furberg,et al.  Lipoprotein Management in Patients With Cardiometabolic Risk , 2008, Diabetes Care.

[43]  A. Kontush,et al.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors , 2009, European heart journal.

[44]  W. Insull.  Clinical Utility of Bile Acid Sequestrants in the Treatment of Dyslipidemia: A Scientific Review , 2006, Southern medical journal.

[45]  S. Offermanns.  The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. , 2006, Trends in pharmacological sciences.

[46]  R. Knopp.  Drug treatment of lipid disorders. , 1999, The New England journal of medicine.